Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.11) by 36.36 percent. This is a 200 percent decrease over losses of $(0.05) per share from the same period last year.
Barclays Maintains Overweight on JPMorgan Chase, Lowers Price Target to $162
Barclays analyst Jason Goldberg maintains JPMorgan Chase (NYSE:JPM) with a Overweight and lowers the price target from $200 to $162.
